康達新材(002669.SZ):公司產品未應用於peek領域
格隆匯1月4日丨康達新材(002669.SZ)在投資者互動平台表示,公司膠粘劑與特種樹脂新材料板塊主營業務產品涵蓋環氧樹脂膠、聚氨酯膠、丙烯酸酯膠、SBS膠、熱熔膠、水性膠等多個膠粘劑系列,環氧樹脂、聚氨酯樹脂等特種樹脂系列及環氧樹脂複合材料、聚氨酯複合材料等新材料系列,產品廣泛應用於風電葉片製造、包裝材料、軌道交通、船舶工程、汽車、電子電器等領域。公司產品未應用於peek領域。公司持股比例為10%的參股公司合肥東華復材科技有限公司是專注在熱塑性碳纖維複合材料領域的新型科技企業,主要方向為醫療和汽車領域的產業應用,其熱塑性碳纖維複合材料採用聚醚醚酮作為合成材料之一。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.